Evidence map›Paper›PMID 39617681›Full record

ArticleUrologic oncology2025

Exploring prostate-specific antigen (PSA) Testing rates and screening disparities in the all of us dataset.

Jonathan T Ryan, William Jin, Joao G Porto, Dinno Mendiola, Tarek Ajami, Hui Yu, Brandon A Mahal, Sanoj Punnen

Abstract read
In one paragraph

Article in Urologic oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jonathan T RyanDr. Kiran C. Patel College of Allopathic Medicine (NSU MD), Davie, FL; Desai Sethi Urology Institute and Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
William JinDepartment of Radiation Oncology, Sylvester Comprehensive Cancer Center, Miami, FL.
Joao G PortoDesai Sethi Urology Institute and Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
Dinno MendiolaDesai Sethi Urology Institute and Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
Tarek AjamiDesai Sethi Urology Institute and Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
Hui YuDepartment of Public Health Sciences, Sylvester Comprehensive Cancer Center, Miami, FL.
Brandon A MahalDepartment of Radiation Oncology, Sylvester Comprehensive Cancer Center, Miami, FL.
Sanoj PunnenDesai Sethi Urology Institute and Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL. Electronic address: s.punnen@med.miami.edu.

Funding

Tumor Biology Research ProgramP30CA240139 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Stephen D. Nimer · 2019 to 2026
$24.1M
UM Calabresi Clinical Oncology Research Career Development AwardK12CA226330 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Alan Pollack · 2018 to 2026
$5.1M
MRI Imaging and Biomarkers for Early Detection of Aggressive Prostate CancerU01CA239141 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI POLLACK, ALAN, PUNNEN, SANOJ · 2019 to 2023
$3.0M
The Rigor and Clinical Utility of PSMA Enriched Extracellular Vesicles for Prostate Cancer DetectionR01CA272766 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SANDRA M GASTON, Alan Pollack · 2023 to 2026
$1.9M
NCI NIH HHS K12 CA226330NCI NIH HHS P30 CA240139NCI NIH HHS R01 CA272766NCI NIH HHS U01 CA239141
6 · The paper itself

Abstract

purposeTo examine prostate cancer (PCa) screening disparities among ethnic groups in the U.S. using the All of Us database. MATERIAL AND

methodsWhite, Black, Hispanic, and Asian males ≥ 40 years old were included, excluding diagnosis's that conflict with PCa screening. We analyzed prostate-specific antigen (PSA) screening rates by age based on American Urological Association guidelines, using multivariable logistic regression (MLR) and a Cox time-to-event models that considered race, age, income, education, insurance, and home ownership as independent variables. Initial screening ages and biopsy rates were also compared.

resultsOf 56,473 individuals, 18,088 had PSA measurements: 74% White, 15% Black, 9% Hispanic, and 2% Asian. Hispanic (20%) and Black (21%) minorities were less likely to undergo PSA screening compared to White men (39%, P < 0.001). However, minorities had their initial PSA earlier with their first test from 53-54 years old compared to White men at 58 years (P < 0.001). MLR revealed race, age, income, education, insurance type, and home ownership as screening predictors (P < 0.001). Screened Black men had higher odds of an elevated PSA (P < 0.001), but the likelihood of receiving a biopsy postelevated PSA did not significantly differ from White men (P = 0.821). Additionally, those screened at age ≥ 70 were more likely to be White, have at least a college education, and be homeowners (P < 0.001).

conclusionsWhite men, despite starting at a later age, are screened with PSAs more frequently than minorities, and often undergo screening at older ages outside the recommended guidelines. Black men did not have a higher rate of biopsy after having an elevated PSA compared to White men.

Indexed as

Early Detection of CancerHealthcare DisparitiesProstate-Specific AntigenProstatic NeoplasmsAdultAgedHumansMaleMass ScreeningMiddle AgedUnited StatesProstate-Specific AntigenCancer screeningEarly detection of cancerHealth disparitiesProstate cancerProstate-specific antigen

Identifiers

PMID39617681
PMCPMC11875933

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.